Genmab A/S
GNMSF
$241.84
-$3.16-1.29%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 22.48% | 24.87% | 30.35% | 19.66% | 21.11% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 22.48% | 24.87% | 30.35% | 19.66% | 21.11% |
| Cost of Revenue | 121.17% | 164.89% | 337.23% | 676.55% | 2,661.37% |
| Gross Profit | 19.35% | 21.56% | 26.09% | 15.66% | 17.55% |
| SG&A Expenses | 11.96% | 10.80% | 16.98% | 9.77% | 18.13% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.55% | 22.05% | 30.04% | 26.88% | 36.17% |
| Operating Income | 35.21% | 30.85% | 31.01% | 7.10% | -2.14% |
| Income Before Tax | 31.50% | 27.84% | 61.25% | 26.56% | 35.14% |
| Income Tax Expenses | -41.57% | -21.60% | 3.18% | 79.72% | 77.56% |
| Earnings from Continuing Operations | 57.64% | 42.50% | 78.38% | 13.24% | 24.50% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 57.64% | 42.50% | 78.38% | 13.24% | 24.50% |
| EBIT | 35.21% | 30.85% | 31.01% | 7.10% | -2.14% |
| EBITDA | 35.47% | 31.39% | 31.69% | 7.46% | -1.74% |
| EPS Basic | 62.41% | 45.79% | 82.26% | 14.75% | 25.07% |
| Normalized Basic EPS | 39.27% | 38.25% | 66.77% | 21.14% | 25.87% |
| EPS Diluted | 62.63% | 45.95% | 82.42% | 14.96% | 25.26% |
| Normalized Diluted EPS | 39.47% | 38.45% | 66.96% | 21.36% | 26.07% |
| Average Basic Shares Outstanding | -2.86% | -2.13% | -1.91% | -1.19% | -0.49% |
| Average Diluted Shares Outstanding | -3.09% | -2.36% | -2.04% | -1.32% | -0.59% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |